Search or
𝛼SK
𝛼SKJiangsu Hengrui Pharma A/H Trading - Strong Demand for Quality Asset, but Is Pricey
416 Views23 May 2025 07:07
Jiangsu Hengrui Pharmaceuticals (1276 HK) (JHP, 600276 CH ), a China-based pharmaceutical company, raised around US$1.5bn in its H-share listing. In this note, we talk about the trading dynamics.
What is covered in the Full Insight:
- Introduction
- Deal Dynamics
- Past Deal Performance
- Current Trading Position
- Valuation and Conclusion
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Lens Technology A/H Listing - Diversifying but Is Tarrified for Now29 May 2025
- Seres Group A/H Listing - Rapid Growth but Its Partner’s Sanctions Risk Might Keep Some Away28 May 2025
- Hengrui Pharma (1276 HK): Trying to Achieve Total Global Index Inclusion27 May 2025
- CATL A/H Trading - Strong Demand, Upsized, Included in Short-Sell List20 May 2025
- Jiangsu Hengrui Pharma A/H Listing - Low-End Is Probably Close to Fair Value15 May 2025
- Jiangsu Hengrui Pharma A/H Listing - PHIP Updates and Updated Thoughts on A/H Premium08 May 2025
x